BPC-157 + TB-500 Research Spray Kit (10mg/7ml)

This kit supplies a two-component blend of BPC-157 and TB-500, 5 mg of each, with reconstitution solution and a spray bottle. The components have separate literatures and separate proposed mechanisms; no study characterises the combination.

BPC-157 is a synthetic pentadecapeptide derived from a gastric juice protein fragment. No high-affinity receptor has been established for it; the most developed mechanistic account is upregulation of VEGFR2 signalling and associated angiogenesis, which would explain the recurring observation of accelerated vascular ingrowth across otherwise unrelated injury models.

TB-500 corresponds to the actin-binding region of thymosin beta-4, the principal G-actin sequestering protein in mammalian cells. By binding monomeric actin it influences the polymerisation equilibrium that governs cell migration and cytoskeletal remodelling — a mechanism quite different from BPC-157's, and one that operates intracellularly.

The rationale for combining them is that angiogenesis and cell migration are complementary requirements in tissue repair. That rationale is plausible but has not been tested: additivity and synergy are both unestablished for this pairing.

Findings below are drawn from published preclinical and clinical work and are presented for research context only.

• BPC-157 angiogenesis. VEGFR2-associated signalling and vascular ingrowth are reported across tendon, ligament, muscle and gastrointestinal injury models.

• Thymosin beta-4 actin binding. The parent protein sequesters G-actin and influences polymerisation dynamics, with a literature covering corneal, dermal and cardiac repair.

• Intra-articular work. Recent work has examined BPC-157 by intra-articular injection across several joint injury types.

• No combination data. No published study characterises this two-component blend. Any account of combined behaviour is inference from the separate literatures.

• Evidence caveat. Both components are supported predominantly by preclinical rodent work, and BPC-157's literature is concentrated among a small number of research groups.

This section describes laboratory handling. It is not clinical guidance, and no safety claim for human or veterinary administration is made or implied.

• Reconstitute the lyophilized vial with the supplied solution before transferring to the spray bottle. Working stability in the spray bottle is shorter than that of the sealed vial; prepare only what the protocol requires.

• Handle as a research chemical of undetermined hazard. Use gloves, eye protection and a laboratory coat.

• Storage temperature and, where applicable, reconstitution conditions are stated on the item specification sheet and the lot Certificate of Analysis, which take precedence over general guidance.

• Dispose of unused material and consumables in accordance with the institutional chemical waste policy.

For laboratory research use only. Not for human or veterinary use. Not a drug, food, cosmetic or dietary supplement.

This kit supplies a 5 mg / 5 mg blend of BPC-157 and TB-500 with reconstitution solution and a spray bottle. The blend carries no single molecular formula; component quantities are recorded on the lot Certificate of Analysis.

The components act through unrelated mechanisms — angiogenic signalling for BPC-157, actin sequestration for TB-500 — and the rationale for combining them rests on their being complementary requirements in tissue repair. That rationale has not been tested directly.

1. Lin C, Qiu L, Wang P, Zhang B, Yan L, Zhao C. Thymosin beta-4 participate in antibacterial immunity and wound healing in black tiger shrimp, Penaeus monodon. Fish Shellfish Immunol. 2023;141:109065.

2. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13.

3. Sosne G. Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther. 2018;18(sup1):99-104.

4. Carion TW, Ebrahim AS, Kracht D, Agrawal A, Strand E, Kaddurah O, et al. Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy Improves Pseudomonas aeruginosa-Induced Keratitis. Cells. 2018;7(10).

5. Sosne G, Rimmer D, Kleinman HK, Ousler G. Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy, Dry Eye, and Ocular Surface Diseases. Vitam Horm. 2016;102:277-306.

6. Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, Chien KR, et al. Thymosin beta-4 is essential for coronary vessel development and promotes neovascularization via adult epicardium. Ann N Y Acad Sci. 2007;1112:171-88.

7. Sosne G, Qiu P, Kurpakus-Wheater M. Thymosin beta-4 and the eye: I can see clearly now the pain is gone. Ann N Y Acad Sci. 2007;1112:114-22.